VDR
ENSG00000111424
Target class
Nuclear receptor
Chromosome
12
Approved drugs
7
Clinical candidates (approved and in development)
18
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 18
- Chemical probe available
- Yes
- Target name
- VDR
- Gene name
- Vitamin D receptor
- Gene symbol
- VDR
- Protein name
- Vitamin D3 receptor (VDR) (1,25-dihydroxyvitamin D3 receptor) (Nuclear receptor subfamily 1 group I member 1)
- NR1I1
- PPP1R163
- Gene biotype
- Protein coding
- Gene family
- Protein phosphatase 1 regulatory subunits|Nuclear receptor subfamily 1 group I
- Target class
- Nuclear receptor
- Target type
- Human gene
- Tissues expressed in
- 36
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 32.05
- Tissue specificity (Gini)
- 0.658
- Tissue specificity (tau)
- 0.837
- KEGG gene identifiers
- hsa:7421
- R-HSA-196791
- R-HSA-383280
- R-HSA-4090294
- End position
- 47943048
- Start position
- 47841537
- Chromosome
- 12
- Strand
- Reverse
- Nucleus . Cytoplasm . Note=Localizes mainly to the nucleus (PubMed:12145331, PubMed:28698609). Translocated into the nucleus via both ligand-dependent and ligand-independent pathways
- ligand-independent nuclear translocation is mediated by IPO4 (PubMed:16207705). .
- Cytosol
- Nucleoplasm
- PubMed 12145331
- PubMed 16207705
- PubMed 28698609
- Tissue specificity (tau)
- 0.837141
- Expression inequality (Gini)
- 0.658115
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)
- 32.05
- Skin - Sun Exposed (Lower leg)
- 28.99
- Small Intestine - Terminal Ileum
- 25.39
- Colon - Transverse
- 22.85
- Cells - Cultured fibroblasts
- 21.31
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)32.05
- Skin - Sun Exposed (Lower leg)28.99
- Small Intestine - Terminal Ileum25.39
- Colon - Transverse22.85
- Cells - Cultured fibroblasts21.31
- Pituitary19.14
- Esophagus - Mucosa17.92
- Vagina13.52
- Lung12.37
- Adrenal Gland11.75
- Kidney - Cortex9.83
- Minor Salivary Gland8.24
- Cells - EBV-transformed lymphocytes7.9
- Whole Blood7.34
- Breast - Mammary Tissue6.41
- Artery - Aorta6.09
- Cervix - Ectocervix5.6
- Bladder4.38
- Thyroid3.74
- Adipose - Subcutaneous3.72
- Spleen3.63
- Artery - Tibial3.45
- Kidney - Medulla3.31
- Cervix - Endocervix3.18
- Artery - Coronary3.12
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0000902
- GO:0008285
- GO:0010628
- GO:0010839
- GO:0035435
- GO:0038185
- GO:0042359
- GO:0042789
- GO:0045618
- GO:0045892
- GO:0045944
- GO:0046697
- GO:0048384
- GO:0070561
- GO:0070564
- GO:1903412
- GO:0000785
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0043235
- GO:0090575
- GO:0003677
- GO:0003700
- GO:0003707
- GO:0004879
- GO:0005515
- GO:0038186
- GO:0046965
- GO:0070644
- GO:1902098
- GO:1902121
regulation of transcription factor activity
- cell-based: TOX21_VDR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene reporter gene substrate used as the measure of target activity.
- cell-based: ATG_VDR_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_VDRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_VDRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: TOX21_VDR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.
- HEK293T, cell line
- HepG2, cell line
Evidence source
Related records
Trials (2,078)
- 'Palliative-D' Vitamin D to Palliative Cancer Patients
- "Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"
- "HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"
- "Information Technology Methodology for Patient Motivation in Diabetes Management."
- "The Effect of Comprehensive Non-pharmacological Treatment on Metabolic Disorders in Type 2 Diabetic Patients"
- [18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis
- 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat
- 18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone
- 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination
- 24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
- 25-Hydroxyvitamin D Pharmacokinetic Study
- 2D/3D Imaging to Analyze the Regeneration Rate of Autologous Bone
- 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial
- 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
- 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
- 30000 IU Per Week Vitamin D Treatment in PCOS Patients
- 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
- 4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)
- 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
Drugs (19)
- Alfacalcidol Vitamin D receptor agonist
- Becocalcidiol Vitamin D receptor agonist
- Calcifediol Vitamin D receptor agonist
- Calcifediol anhydrous Vitamin D receptor agonist
- Calcipotriene Vitamin D receptor agonist
- Calcitriol Vitamin D receptor agonist
- Cholecalciferol Vitamin D receptor agonist
- Dihydrotachysterol Vitamin D receptor agonist
- Doxercalciferol Vitamin D receptor agonist
- DP001 Vitamin D receptor agonist
- Eldecalcitol Vitamin D receptor agonist
- Elocalcitol Vitamin D receptor agonist
- Ergocalciferol Vitamin D receptor agonist
- ILX23-7553 Vitamin D receptor agonist
- Inecalcitol Vitamin D receptor agonist
- Lunacalcipol Vitamin D receptor agonist
- Paricalcitol Vitamin D receptor agonist
- Pefcalcitol Vitamin D receptor agonist
- Seocalcitol Vitamin D receptor agonist